Autoimmune Technologies - Applied Biomedical Science

Viral Entry Inhibition

Autoimmune Technologies and Tulane University's School of Medicine are working jointly on using small isolated peptides to inhibit the entry of viral particles into their target cells. This very powerful method of combating viral infection may lead to highly-effective new drugs for troublesome and dangerous viral diseases.

In order to infect their target cells, viral particles must first attach themselves to the cell surface membranes and fuse with the cells. If this binding and fusion process is disrupted, the viral particles cannot enter and infect the intended host cells. Autoimmune and Tulane have found that certain characteristics of the surface proteins of many viruses render these viruses highly susceptible to entry-inhibiting peptides. To date the researchers have used carefully-designed peptides to inhibit viral infection at very low peptide concentrations in more than a dozen different important viruses.

Among the peptides now being studied for use in entry-inhibiting drugs are peptides designed against the influenza, MERS/SARS, HIV-1, hepatitis C, measles, Dengue fever and West Nile fever viruses.

For more information about FF-3, the Company's new entry-inhibiting peptide influenza drug, click here.


This material is not intended to take the place of a physician's advice.


Web site by: New Orleans Web Design